Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could your gut bacteria be linked to eye disease?

NCT ID NCT01859299

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 16, 2026 · Updated 11 times

Summary

This study looked at the natural bacteria in the gut of 131 adults with and without uveitis, an inflammatory eye disease. Researchers collected stool and blood samples and performed eye exams to see if differences in gut bacteria are linked to eye inflammation. No treatment was given; the goal was simply to gather information.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could point toward new ways to treat or prevent uveitis by targeting gut bacteria.
What could go wrong
This is an observational study, not a treatment trial. It only looks for links between gut bacteria and eye inflammation, so it may not lead to any direct medical advances.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

131 people

The number who actually took part.

Started

Aug 2013

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

200 participants: 150 with uveitis; 50 healthy controls

Ages

18 to 120 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: Inclusion Criteria for Uveitis Participants 1. Participant must be 18 years of age or older. 2. Participant must have a diagnosis of: Uveitis (or ocular inflammatory disorder) 3. Participant must be able to undergo slit lamp biomicroscopy. 4. Participant must understand and sign the protocol s informed consent document. Inclusion Criteria for Healthy Volunteers 1. Participant must be 18 years of age or older. 2. Participant must be able to undergo slit lamp biomicroscopy. 3. Healthy controls will be age-and sex-matched individuals with no personal history of uveitis or other rheumatologic/autoimmune diseases (such as arthritis, inflammatory bowel disease, type 1 diabetes mellitus, psoriasis, Sjorgren s syndrome or multiple sclerosis) and no current use of corticosteroids, disease modifying antirheumatic drugs (DMARDs) including those with antibiotic properties (e.g., gold salts, sulfasalazine, hydroxychloroquine, minocycline) or any immunomodulatory drugs. 4. Participant must understand and sign the protocol s informed consent document. EXCLUSION CRITERIA: Exclusion Criteria for Uveitis Participants 1. Participants who are unable to provide informed consent. 2. Recent (\<3 months prior) use of any antibiotic therapy 3. Current consumption of probiotics 4. Current extreme diet (parenteral nutrition, macrobiotic diet, etc.) 5. Known gastrointestinal (GI) tract neoplasm 6. Recent GI tract infection (gastroenteritis, colitis, diverticulitis, appendicitis) within the last month 7. Chronic unexplained diarrhea 8. Participant has or had a significant active infection (an infection requiring treatment as determined by the investigator) that required systemic antibiotic treatment within the past three months 9. Participant has any GI tract surgery leaving permanent residua (e.g., gastrectomy; bariatric surgery; colectomy) 10. Participant has inflammatory bowel disease (IBD) 11. Participant is pregnant or lactating. Exclusion Criteria for Healthy Volunteers 1. Recent (\<3 months prior) use of any antibiotic therapy 2. Current consumption of probiotics 3. Current extreme diet (parenteral nutrition, macrobiotic diet, etc.) 4. Known gastrointestinal (GI) tract neoplasm 5. Recent GI tract infection (gastroenteritis, colitis, diverticulitis, appendicitis) within the last month 6. Chronic unexplained diarrhea 7. Participant has or had a significant active infection (an infection requiring treatment as determined by the investigator) that required systemic antibiotic treatment within the past three months 8. Participant has any GI tract surgery leaving permanent residua (e.g., gastrectomy; bariatric surgery; colectomy) 9. Participant has inflammatory bowel disease (IBD) 10. Participant is pregnant or lactating.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Uveitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.